315-30-0
315-30-0
Chemical Structure
Allopurinol
- CAS No.: 315-30-0
- Formula:C5H4N4O
- Molecular Weight:136.11
IUPAC Name: 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one
InChIKey: OFCNXPDARWKPPY-UHFFFAOYSA-N
SMILES: O=C1C2=C(NN=C2)N=CN1
Biological Activity: Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Allopurinol | 99.96% | Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Allopurinol (Standard) | 99.97% | Allopurinol (Standard) is the analytical standard of Allopurinol. This product is intended for research and analytical applications. Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Allopurinol-d2 | 98.36% | Allopurinol-d2 is deuterium labeled Allopurinol. Allopurinol is a potent xanthine oxidase inhibitor (IC50 values of 0.2 to 50 μM). Allopurinol can be used for the research of hyperuricemia and gout. Antileishmanial effect. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Allopurinol-13C,15N2 | Allopurinol-13C,15N2 is the 13C- and 15N-labeled labeled Allopurinol (HY-B0219). Allopurinol is a potent and orally active xanthine oxidase inhibitor with an IC50 value of 0.2-50 μM. Allopurinol can be used in the research of hyperuricemia and gout. Allopurinol decreases the expression of HIF-1α and HIF-2α protein. Allopurinol shows anti-depressant and anti-nociception activity. Anti-leishmanial effect. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pacher P, et al. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006 Mar;58(1):87-114. [Content Brief]
- [2]. Pfaller MA, et al. Antileishmanial effect of allopurinol. Antimicrob Agents Chemother. 1974;5(5):469-472. [Content Brief]
- [3]. Karve AV, et al. Evaluation of effect of allopurinol and febuxostat in behavioral model of depression in mice. Indian J Pharmacol. 2013 May-Jun;45(3):244-7. [Content Brief]
- [4]. Schmidt AP, et al. Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors. Br J Pharmacol. 2009 Jan;156(1):163-72. [Content Brief]
- [5]. Sun Y, et al. Dose-dependent effects of allopurinol on human foreskin fibroblast cells and human umbilical vein endothelial cells under hypoxia. PLoS One. 2015 Apr 1;10(4):e0123649. [Content Brief]
